Variablea | Heallagen (n = 30) | Placebo (n = 30) | Pb | P-adjusted 1c | |
---|---|---|---|---|---|
Neutrophil (%) | Baseline | 63.62 ± 7.28 | 65.4 ± 11.17 | 0.469 | 0.682 |
End of the study | 82.95 ± 9.29 | 79.62 ± 9.04 | 0.165 | 0.138 | |
Changes | 19.32 ± 10.20 | 14.22 ± 13.83 | 0.035* | 0.033¥ | |
Pd | < 0.001 | < 0.001 | |||
Lymphocyte (%) | Baseline | 30.51 ± 8.08 | 29.49 ± 10.53 | 0.677 | 0.811 |
End of the study | 11.54 ± 8.06 | 21.70 ± 20.69 | 0.007** | 0.006** | |
Changes | − 18.97 ± 9.68 | − 7.79 ± 26.39 | 0.080* | 0.085¥ | |
Pd | < 0.001 | 0.117 | |||
Platelet (103/mm3) | Baseline | 187.16 ± 41.90 | 196.43 ± 53.22 | 0.480** | 0.770¥ |
End of the study | 164.46 ± 52.73 | 158.83 ± 29.64 | 0.410* | 0.909¥ | |
Changes | − 22.70 ± 65.68 | -37.60 ± 47.45 | 0.988* | 0.949¥ | |
Pd | 0.057* | < 0.001* | |||
RBC (cells/mm3) | Baseline | 4.85 ± 0.62 | 4.64 ± 0.65 | 0.536 | 0.702 |
End of the study | 3.67 ± 0.90 | 3.54 ± 0.73 | 0.728* | 0.749¥ | |
Changes | − 1.17 ± 1.04 | − 1.09 ± 0.84 | 0.765 | 0.812 | |
Pd | < 0.001* | < 0.001* | |||
WBC (cells/mm3) | Baseline | 6746.66 ± 1361.47 | 6834.00 ± 1903.15 | 0.839 | 0.714 |
End of the study | 11,421.33 ± 4760.87 | 10,122.16 ± 4124.20 | 0.459* | 0.772¥ | |
Changes | 4674.66 ± 4330.44 | 3288.16 ± 3817.91 | 0.379* | 0.611¥ | |
Pd | < 0.001* | < 0.001* | |||
BUN (mmol/L) | Baseline | 16.83 ± 5.38 | 14.77 ± 4.29 | 0.107 | 0.112 |
End of the study | 16.59 ± 5.16 | 14.29 ± 3.74 | 0.064** | 0.050** | |
Changes | − 0.24 ± 4.88 | − 0.48 ± 3.74 | 0.832 | 0.691 | |
Pd | 0.787 | 0.485 | |||
Creatinine (mmol/L) | Baseline | 1.28 ± 1.28 | 1.01 ± 0.24 | 0.255* | 0.633¥ |
End of the study | 1.23 ± 1.31 | 1.44 ± 1.06 | 0.089* | 0.091¥ | |
Changes | − 0.04 ± 0.28 | 0.43 ± 1.13 | 0.054* | 0.208¥ | |
Pd | 0.402* | 0.060* |